Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Fortunately, the FDA has approved antipsychotic treatments that help manage these destructive symptoms, and more are in ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Antipsychotics are the best defense against relapse in schizophrenia, even though that protection often comes at the expense ...

There are many mechanisms at work here, but the blood sugar increase is probably secondary to the weight gain, rather than ...

anti-anxiety medications, antipsychotics, stimulants, and mood stabilizers. These categories of medications are generally ...

Management of adverse events is a major concern of clinicians who use antipsychotic drugs. The incidence of motor side effects is dose dependent. Atypical antipsychotic drugs are less likely to ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

A new report that lists what it calls the best nursing homes in the US finds that top-rated facilities continuously excel ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Resulting data from 9,525 participants determined that while antipsychotics as a group showed slight cognitive benefits, no individual drug demonstrated a substantial advantage over placebo.